Global COVID-19 Diagnostic Testing Market

COVID-19 Diagnostic Testing Comprehensive Study by Type (Nucleic Acid Testing, Molecular (PCR) Testing, Antigen-based Testing, Antibody (Serology) Testing, Others), Sample Type (Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Nasal Swabs, Blood, Others), Mode (Point-of-Care (POC), Non-Point-of-Care (Non-POC)), End User (Laboratories, Hospitals, Diagnostic Centers and Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2028

COVID-19 Diagnostic Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
COVID-19 Diagnostic Testing is critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection. Over 600 SARS-CoV-2 diagnostic tests are either approved or are in the development phase for clinical use. Therefore, an increase in the need for developing diagnostic tests is anticipated to drive the market growth. The current status of lead COVID tests is toward rising capacity but mixed accuracy. For efficient and accurate COVID-19 diagnosis testing, clinicians need a portable or an on-site diagnostic test for real-time management of patients in minimal time. This has encouraged the adoption of Point-of-Care (POC) testing for diagnosis. A growing number of COVID-19 cases ass over the world is the major driving factor for the COVID-19 diagnostic testing market.

Highlights from COVID-19 Diagnostic Testing Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The key Players profiled in the report are Abbott Laboratories (United States), F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (United States), Perkin Elmer, Inc. (United States), BioMedomics, Inc. (United States), Aldatu Biosciences Inc. (United States), Quidel Corporation (United States), Quest Diagnostics (United States), Hologic Inc (United States), Laboratory Corporation of America Holdings (United States), Luminex Corporation (United States) and Cepheid (United States). Additionally, other players that are part of this comprehensive study are altona Diagnostics GmbH (Germany), Neuberg Diagnostics (India), 1drop Inc. (South Korea), Veredus Laboratories (Singapore), ADT Biotech (Malaysia), bioMérieux SA (France), Danaher (United States) and Mylab Discovery Solutions Pvt Ltd. (India).

Geographic Breakdown and Segment Analysis
The Global COVID-19 Diagnostic Testing market presents a comprehensive analysis of the COVID-19 Diagnostic Testing market by product type (Nucleic Acid Testing, Molecular (PCR) Testing, Antigen-based Testing, Antibody (Serology) Testing and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global COVID-19 Diagnostic Testing industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the COVID-19 Diagnostic Testing market

Analyst at AMA have segmented the market study of Global COVID-19 Diagnostic Testing market by Type, Application and Region.

Influencing Trend:
Rising Inclined Toward Incorporating Artificial Intelligence (AI) Algorithms in the COVID-19 Tests for Rapid and Efficient Diagnosis

Market Growth Drivers:
Robust Funding and Investments by the Public as well as Private Agencies are Expected to Propel Molecular Diagnostic Companies to Develop COVID-19 Diagnostic Testing and Increasing Focusing On Developing Rapid Immunoassay Tests for Covid-19 Diagnosis

Challenges:
Intense Competition among the Competitors

Restraints:
Strict Government Rules and Regulations

Opportunities:
Technological Development and Advancement in the COVID-19 Diagnostic Testing and Rising Demand from the Developing Economies like India

Market Developments Activities:
In July 2020, Becton, Dickinson, and Company launched a point-of-care SARS-CoV-2 diagnostic test as a response to the growing need for rapid testing. This test enables real-time testing of patients using an easy-to-use, highly portable instrument.
For instance, in June 2020, NIH has announced to release of four funding opportunities to accelerate research on SARS-COV-2 screening for vulnerable and underserved populations to decipher and address the disparity gap.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Target Audience
Diagnostic Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Report Objectives / Segmentation Covered

By Type
  • Nucleic Acid Testing
  • Molecular (PCR) Testing
  • Antigen-based Testing
  • Antibody (Serology) Testing
  • Others
By Sample Type
  • Nasopharyngeal (NP) Swab
  • Oropharyngeal (OP) Swab
  • Nasal Swabs
  • Blood
  • Others

By Mode
  • Point-of-Care (POC)
  • Non-Point-of-Care (Non-POC)

By End User
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Robust Funding and Investments by the Public as well as Private Agencies are Expected to Propel Molecular Diagnostic Companies to Develop COVID-19 Diagnostic Testing
      • 3.2.2. Increasing Focusing On Developing Rapid Immunoassay Tests for Covid-19 Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. Intense Competition among the Competitors
    • 3.4. Market Trends
      • 3.4.1. Rising Inclined Toward Incorporating Artificial Intelligence (AI) Algorithms in the COVID-19 Tests for Rapid and Efficient Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global COVID-19 Diagnostic Testing, by Type, Sample Type, Mode, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global COVID-19 Diagnostic Testing (Value)
      • 5.2.1. Global COVID-19 Diagnostic Testing by: Type (Value)
        • 5.2.1.1. Nucleic Acid Testing
        • 5.2.1.2. Molecular (PCR) Testing
        • 5.2.1.3. Antigen-based Testing
        • 5.2.1.4. Antibody (Serology) Testing
        • 5.2.1.5. Others
      • 5.2.2. Global COVID-19 Diagnostic Testing by: Sample Type (Value)
        • 5.2.2.1. Nasopharyngeal (NP) Swab
        • 5.2.2.2. Oropharyngeal (OP) Swab
        • 5.2.2.3. Nasal Swabs
        • 5.2.2.4. Blood
        • 5.2.2.5. Others
      • 5.2.3. Global COVID-19 Diagnostic Testing by: Mode (Value)
        • 5.2.3.1. Point-of-Care (POC)
        • 5.2.3.2. Non-Point-of-Care (Non-POC)
      • 5.2.4. Global COVID-19 Diagnostic Testing by: End User (Value)
        • 5.2.4.1. Laboratories
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Diagnostic Centers and Clinics
        • 5.2.4.4. Research Institutes
        • 5.2.4.5. Others
      • 5.2.5. Global COVID-19 Diagnostic Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. COVID-19 Diagnostic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Perkin Elmer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioMedomics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aldatu Biosciences Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quidel Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Quest Diagnostics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hologic Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Laboratory Corporation of America Holdings (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Luminex Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Cepheid (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global COVID-19 Diagnostic Testing Sale, by Type, Sample Type, Mode, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global COVID-19 Diagnostic Testing (Value)
      • 7.2.1. Global COVID-19 Diagnostic Testing by: Type (Value)
        • 7.2.1.1. Nucleic Acid Testing
        • 7.2.1.2. Molecular (PCR) Testing
        • 7.2.1.3. Antigen-based Testing
        • 7.2.1.4. Antibody (Serology) Testing
        • 7.2.1.5. Others
      • 7.2.2. Global COVID-19 Diagnostic Testing by: Sample Type (Value)
        • 7.2.2.1. Nasopharyngeal (NP) Swab
        • 7.2.2.2. Oropharyngeal (OP) Swab
        • 7.2.2.3. Nasal Swabs
        • 7.2.2.4. Blood
        • 7.2.2.5. Others
      • 7.2.3. Global COVID-19 Diagnostic Testing by: Mode (Value)
        • 7.2.3.1. Point-of-Care (POC)
        • 7.2.3.2. Non-Point-of-Care (Non-POC)
      • 7.2.4. Global COVID-19 Diagnostic Testing by: End User (Value)
        • 7.2.4.1. Laboratories
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Diagnostic Centers and Clinics
        • 7.2.4.4. Research Institutes
        • 7.2.4.5. Others
      • 7.2.5. Global COVID-19 Diagnostic Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. COVID-19 Diagnostic Testing: by Type(USD Million)
  • Table 2. COVID-19 Diagnostic Testing Nucleic Acid Testing , by Region USD Million (2017-2022)
  • Table 3. COVID-19 Diagnostic Testing Molecular (PCR) Testing , by Region USD Million (2017-2022)
  • Table 4. COVID-19 Diagnostic Testing Antigen-based Testing , by Region USD Million (2017-2022)
  • Table 5. COVID-19 Diagnostic Testing Antibody (Serology) Testing , by Region USD Million (2017-2022)
  • Table 6. COVID-19 Diagnostic Testing Others , by Region USD Million (2017-2022)
  • Table 7. COVID-19 Diagnostic Testing: by Sample Type(USD Million)
  • Table 8. COVID-19 Diagnostic Testing Nasopharyngeal (NP) Swab , by Region USD Million (2017-2022)
  • Table 9. COVID-19 Diagnostic Testing Oropharyngeal (OP) Swab , by Region USD Million (2017-2022)
  • Table 10. COVID-19 Diagnostic Testing Nasal Swabs , by Region USD Million (2017-2022)
  • Table 11. COVID-19 Diagnostic Testing Blood , by Region USD Million (2017-2022)
  • Table 12. COVID-19 Diagnostic Testing Others , by Region USD Million (2017-2022)
  • Table 13. COVID-19 Diagnostic Testing: by Mode(USD Million)
  • Table 14. COVID-19 Diagnostic Testing Point-of-Care (POC) , by Region USD Million (2017-2022)
  • Table 15. COVID-19 Diagnostic Testing Non-Point-of-Care (Non-POC) , by Region USD Million (2017-2022)
  • Table 16. COVID-19 Diagnostic Testing: by End User(USD Million)
  • Table 17. COVID-19 Diagnostic Testing Laboratories , by Region USD Million (2017-2022)
  • Table 18. COVID-19 Diagnostic Testing Hospitals , by Region USD Million (2017-2022)
  • Table 19. COVID-19 Diagnostic Testing Diagnostic Centers and Clinics , by Region USD Million (2017-2022)
  • Table 20. COVID-19 Diagnostic Testing Research Institutes , by Region USD Million (2017-2022)
  • Table 21. COVID-19 Diagnostic Testing Others , by Region USD Million (2017-2022)
  • Table 22. South America COVID-19 Diagnostic Testing, by Country USD Million (2017-2022)
  • Table 23. South America COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 24. South America COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 25. South America COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 26. South America COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 27. Brazil COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 28. Brazil COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 29. Brazil COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 30. Brazil COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 31. Argentina COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 32. Argentina COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 33. Argentina COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 34. Argentina COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 35. Rest of South America COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 36. Rest of South America COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 37. Rest of South America COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 38. Rest of South America COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 39. Asia Pacific COVID-19 Diagnostic Testing, by Country USD Million (2017-2022)
  • Table 40. Asia Pacific COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 41. Asia Pacific COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 42. Asia Pacific COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 43. Asia Pacific COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 44. China COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 45. China COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 46. China COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 47. China COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 48. Japan COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 49. Japan COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 50. Japan COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 51. Japan COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 52. India COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 53. India COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 54. India COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 55. India COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 56. South Korea COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 57. South Korea COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 58. South Korea COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 59. South Korea COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 60. Taiwan COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 61. Taiwan COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 62. Taiwan COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 63. Taiwan COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 64. Australia COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 65. Australia COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 66. Australia COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 67. Australia COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 72. Europe COVID-19 Diagnostic Testing, by Country USD Million (2017-2022)
  • Table 73. Europe COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 74. Europe COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 75. Europe COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 76. Europe COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 77. Germany COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 78. Germany COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 79. Germany COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 80. Germany COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 81. France COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 82. France COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 83. France COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 84. France COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 85. Italy COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 86. Italy COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 87. Italy COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 88. Italy COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 89. United Kingdom COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 90. United Kingdom COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 91. United Kingdom COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 92. United Kingdom COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 93. Netherlands COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 94. Netherlands COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 95. Netherlands COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 96. Netherlands COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 97. Rest of Europe COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 98. Rest of Europe COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 99. Rest of Europe COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 100. Rest of Europe COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 101. MEA COVID-19 Diagnostic Testing, by Country USD Million (2017-2022)
  • Table 102. MEA COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 103. MEA COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 104. MEA COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 105. MEA COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 106. Middle East COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 107. Middle East COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 108. Middle East COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 109. Middle East COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 110. Africa COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 111. Africa COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 112. Africa COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 113. Africa COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 114. North America COVID-19 Diagnostic Testing, by Country USD Million (2017-2022)
  • Table 115. North America COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 116. North America COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 117. North America COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 118. North America COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 119. United States COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 120. United States COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 121. United States COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 122. United States COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 123. Canada COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 124. Canada COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 125. Canada COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 126. Canada COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 127. Mexico COVID-19 Diagnostic Testing, by Type USD Million (2017-2022)
  • Table 128. Mexico COVID-19 Diagnostic Testing, by Sample Type USD Million (2017-2022)
  • Table 129. Mexico COVID-19 Diagnostic Testing, by Mode USD Million (2017-2022)
  • Table 130. Mexico COVID-19 Diagnostic Testing, by End User USD Million (2017-2022)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. COVID-19 Diagnostic Testing: by Type(USD Million)
  • Table 144. COVID-19 Diagnostic Testing Nucleic Acid Testing , by Region USD Million (2023-2028)
  • Table 145. COVID-19 Diagnostic Testing Molecular (PCR) Testing , by Region USD Million (2023-2028)
  • Table 146. COVID-19 Diagnostic Testing Antigen-based Testing , by Region USD Million (2023-2028)
  • Table 147. COVID-19 Diagnostic Testing Antibody (Serology) Testing , by Region USD Million (2023-2028)
  • Table 148. COVID-19 Diagnostic Testing Others , by Region USD Million (2023-2028)
  • Table 149. COVID-19 Diagnostic Testing: by Sample Type(USD Million)
  • Table 150. COVID-19 Diagnostic Testing Nasopharyngeal (NP) Swab , by Region USD Million (2023-2028)
  • Table 151. COVID-19 Diagnostic Testing Oropharyngeal (OP) Swab , by Region USD Million (2023-2028)
  • Table 152. COVID-19 Diagnostic Testing Nasal Swabs , by Region USD Million (2023-2028)
  • Table 153. COVID-19 Diagnostic Testing Blood , by Region USD Million (2023-2028)
  • Table 154. COVID-19 Diagnostic Testing Others , by Region USD Million (2023-2028)
  • Table 155. COVID-19 Diagnostic Testing: by Mode(USD Million)
  • Table 156. COVID-19 Diagnostic Testing Point-of-Care (POC) , by Region USD Million (2023-2028)
  • Table 157. COVID-19 Diagnostic Testing Non-Point-of-Care (Non-POC) , by Region USD Million (2023-2028)
  • Table 158. COVID-19 Diagnostic Testing: by End User(USD Million)
  • Table 159. COVID-19 Diagnostic Testing Laboratories , by Region USD Million (2023-2028)
  • Table 160. COVID-19 Diagnostic Testing Hospitals , by Region USD Million (2023-2028)
  • Table 161. COVID-19 Diagnostic Testing Diagnostic Centers and Clinics , by Region USD Million (2023-2028)
  • Table 162. COVID-19 Diagnostic Testing Research Institutes , by Region USD Million (2023-2028)
  • Table 163. COVID-19 Diagnostic Testing Others , by Region USD Million (2023-2028)
  • Table 164. South America COVID-19 Diagnostic Testing, by Country USD Million (2023-2028)
  • Table 165. South America COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 166. South America COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 167. South America COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 168. South America COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 169. Brazil COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 170. Brazil COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 171. Brazil COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 172. Brazil COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 173. Argentina COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 174. Argentina COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 175. Argentina COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 176. Argentina COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 177. Rest of South America COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 178. Rest of South America COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 179. Rest of South America COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 180. Rest of South America COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 181. Asia Pacific COVID-19 Diagnostic Testing, by Country USD Million (2023-2028)
  • Table 182. Asia Pacific COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 183. Asia Pacific COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 184. Asia Pacific COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 185. Asia Pacific COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 186. China COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 187. China COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 188. China COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 189. China COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 190. Japan COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 191. Japan COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 192. Japan COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 193. Japan COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 194. India COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 195. India COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 196. India COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 197. India COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 198. South Korea COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 199. South Korea COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 200. South Korea COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 201. South Korea COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 202. Taiwan COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 203. Taiwan COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 204. Taiwan COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 205. Taiwan COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 206. Australia COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 207. Australia COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 208. Australia COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 209. Australia COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 210. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 211. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 212. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 213. Rest of Asia-Pacific COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 214. Europe COVID-19 Diagnostic Testing, by Country USD Million (2023-2028)
  • Table 215. Europe COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 216. Europe COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 217. Europe COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 218. Europe COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 219. Germany COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 220. Germany COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 221. Germany COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 222. Germany COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 223. France COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 224. France COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 225. France COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 226. France COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 227. Italy COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 228. Italy COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 229. Italy COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 230. Italy COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 231. United Kingdom COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 232. United Kingdom COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 233. United Kingdom COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 234. United Kingdom COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 235. Netherlands COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 236. Netherlands COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 237. Netherlands COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 238. Netherlands COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 239. Rest of Europe COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 240. Rest of Europe COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 241. Rest of Europe COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 242. Rest of Europe COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 243. MEA COVID-19 Diagnostic Testing, by Country USD Million (2023-2028)
  • Table 244. MEA COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 245. MEA COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 246. MEA COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 247. MEA COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 248. Middle East COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 249. Middle East COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 250. Middle East COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 251. Middle East COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 252. Africa COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 253. Africa COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 254. Africa COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 255. Africa COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 256. North America COVID-19 Diagnostic Testing, by Country USD Million (2023-2028)
  • Table 257. North America COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 258. North America COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 259. North America COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 260. North America COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 261. United States COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 262. United States COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 263. United States COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 264. United States COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 265. Canada COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 266. Canada COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 267. Canada COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 268. Canada COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 269. Mexico COVID-19 Diagnostic Testing, by Type USD Million (2023-2028)
  • Table 270. Mexico COVID-19 Diagnostic Testing, by Sample Type USD Million (2023-2028)
  • Table 271. Mexico COVID-19 Diagnostic Testing, by Mode USD Million (2023-2028)
  • Table 272. Mexico COVID-19 Diagnostic Testing, by End User USD Million (2023-2028)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global COVID-19 Diagnostic Testing: by Type USD Million (2017-2022)
  • Figure 5. Global COVID-19 Diagnostic Testing: by Sample Type USD Million (2017-2022)
  • Figure 6. Global COVID-19 Diagnostic Testing: by Mode USD Million (2017-2022)
  • Figure 7. Global COVID-19 Diagnostic Testing: by End User USD Million (2017-2022)
  • Figure 8. South America COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 9. Asia Pacific COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 10. Europe COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 11. MEA COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 12. North America COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 13. Global COVID-19 Diagnostic Testing share by Players 2022 (%)
  • Figure 14. Global COVID-19 Diagnostic Testing share by Players (Top 3) 2022(%)
  • Figure 15. Global COVID-19 Diagnostic Testing share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 19. F. Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 21. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Perkin Elmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Perkin Elmer, Inc. (United States) Revenue: by Geography 2022
  • Figure 25. BioMedomics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. BioMedomics, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Aldatu Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Aldatu Biosciences Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Quidel Corporation (United States) Revenue: by Geography 2022
  • Figure 31. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Quest Diagnostics (United States) Revenue: by Geography 2022
  • Figure 33. Hologic Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Hologic Inc (United States) Revenue: by Geography 2022
  • Figure 35. Laboratory Corporation of America Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 36. Laboratory Corporation of America Holdings (United States) Revenue: by Geography 2022
  • Figure 37. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Luminex Corporation (United States) Revenue: by Geography 2022
  • Figure 39. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 40. Cepheid (United States) Revenue: by Geography 2022
  • Figure 41. Global COVID-19 Diagnostic Testing: by Type USD Million (2023-2028)
  • Figure 42. Global COVID-19 Diagnostic Testing: by Sample Type USD Million (2023-2028)
  • Figure 43. Global COVID-19 Diagnostic Testing: by Mode USD Million (2023-2028)
  • Figure 44. Global COVID-19 Diagnostic Testing: by End User USD Million (2023-2028)
  • Figure 45. South America COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 46. Asia Pacific COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 47. Europe COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 48. MEA COVID-19 Diagnostic Testing Share (%), by Country
  • Figure 49. North America COVID-19 Diagnostic Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific, Inc. (United States)
  • Perkin Elmer, Inc. (United States)
  • BioMedomics, Inc. (United States)
  • Aldatu Biosciences Inc. (United States)
  • Quidel Corporation (United States)
  • Quest Diagnostics (United States)
  • Hologic Inc (United States)
  • Laboratory Corporation of America Holdings (United States)
  • Luminex Corporation (United States)
  • Cepheid (United States)
Additional players considered in the study are as follows:
altona Diagnostics GmbH (Germany) , Neuberg Diagnostics (India) , 1drop Inc. (South Korea) , Veredus Laboratories (Singapore) , ADT Biotech (Malaysia) , bioMérieux SA (France) , Danaher (United States) , Mylab Discovery Solutions Pvt Ltd. (India)
Select User Access Type

Key Highlights of Report


May 2023 202 Pages 84 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global COVID-19 Diagnostic Testing Market Quantitative research analysis
Global COVID-19 Diagnostic Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Intense Competition among the Competitors

Know More About Global COVID-19 Diagnostic Testing Market Report?

Have a Query? Click Here

Other Related Reports

Bioidentical Hormones Comprehensive Study by Type (Estrogens, Progesterone, Testosterone, Others), Product (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, Others), End User ...
$ 3450
Clonorchis Infection Comprehensive Study by Therapy (Diagnosis (Microscopic Examination, Blood Test, Imaging Examination), Medication (Praziquantel, Albendazole)), Cause (Clonorchis Sinensis, Opistho...
$ 3450
Kidney Disease Comprehensive Study by Type (Chronic Kidney Disease, Acute Kidney Disease), Treatment (Dialysis, Medication, Kidney Transplantation), End-users (Dialysis Centers, Hospital & Clinics, R...
$ 3650
Clonorchiasis Comprehensive Study by Treatment (Praziquantel, Cystic, Biltricide, Others), Parasites (Clonorchis Sinensis, Opisthorchis Viverrini, Opisthorchis Felineus, Others), Diagnosis (Microscop...
$ 3450
Carpal Tunnel Syndrome Comprehensive Study by Drugs (Ibuprofen, Prednisone, Triamcinolone, Others), Treatment (Bracing or Splinting, NSAIDs, Surgical Procedure, Others), End-users (Hospitals, Clinics...
$ 3750
Chapare Hemorrhagic Fever Comprehensive Study by Therapy (Antiviral, Electrolytes, Others), End-users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online...
$ 3350